CYTK director acquires 99 shares at $62.8 under Form 4

Cytokinetics, Inc. (CYTK) reported an insider transaction on Form 4.

Rhea-AI Filing Summary

Cytokinetics, Inc. (CYTK) reported an insider transaction on Form 4. A company director acquired 99 shares of common stock on 10/15/2025 at a price of $62.8 per share. The filing notes the transaction code A (1), with the footnote stating, “Director equity in lieu of cash retainer program,” indicating this was a stock grant in place of cash fees.

Following the transaction, the director now beneficially owns 32,444 shares, held directly. No derivative securities were reported in this filing.

Insider Trade Summary

Grant/Award: 99 shares

Grant/Award 1 txn

Insider WIERENGA WENDELL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	99	$62.80	$6K

Holdings After Transaction: Common Stock — 32,444 shares (Direct)

Footnotes (1)

1. F1. Director equity in lieu of cash retainer program.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CYTK disclose on this Form 4?

A director acquired 99 shares of common stock on 10/15/2025 at $62.8 per share as part of a director equity retainer.

How many CYTK shares does the insider own after the transaction?

Beneficial ownership is 32,444 shares, held directly.

What was the transaction code and what does it signify?

The code was A (1), with a footnote stating “Director equity in lieu of cash retainer program,” indicating a stock grant in place of cash fees.

Was this reported under a 10b5-1 trading plan?

The filing text includes a 10b5-1 checkbox instruction, but the provided content does not indicate it was selected.

Were any derivative securities reported?

No derivative securities were reported in the provided content for Table II.

What is the issuer and ticker for this Form 4?

The issuer is Cytokinetics, Inc. with ticker CYTK.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/21/2025 - 12:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIERENGA WENDELL

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		A(1)		99	A	$62.8	32,444	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Director equity in lieu of cash retainer program.

	/s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.